Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.

Mejías-Pérez E, Carreño-Fuentes L, Esteban M.

Mol Ther Oncolytics. 2017 Dec 5;8:27-40. doi: 10.1016/j.omto.2017.12.002. eCollection 2018 Mar 30.


Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells.

Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Martínez-Cano S, Mejías-Pérez E, Esteban M, Melero I, Hidalgo A, Sancho D.

Nat Commun. 2017 Jul 17;8:16073. doi: 10.1038/ncomms16073.


Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.

Di Pilato M, Mejías-Pérez E, Sorzano COS, Esteban M.

J Virol. 2017 Jun 9;91(13). pii: e00575-17. doi: 10.1128/JVI.00575-17. Print 2017 Jul 1.


A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.

Vijayan A, Mejías-Pérez E, Espinosa DA, Raman SC, Sorzano COS, Zavala F, Esteban M.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00494-16. doi: 10.1128/CVI.00494-16. Print 2017 May.


NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis.

Sánchez-Sampedro L, Mejías-Pérez E, S Sorzano CÓ, Nájera JL, Esteban M.

Virus Res. 2016 Jul 15;220:1-11. doi: 10.1016/j.virusres.2016.03.007. Epub 2016 Mar 29.


Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression.

Di Pilato M, Sánchez-Sampedro L, Mejías-Pérez E, Sorzano CO, Esteban M.

J Gen Virol. 2015 Aug;96(8):2360-71. doi: 10.1099/vir.0.000183. Epub 2015 May 13.


The evolution of poxvirus vaccines.

Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M.

Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726. Review.


NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

Di Pilato M, Mejías-Pérez E, Zonca M, Perdiguero B, Gómez CE, Trakala M, Nieto J, Nájera JL, Sorzano CO, Combadière C, Pantaleo G, Planelles L, Esteban M.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1333-42. doi: 10.1073/pnas.1424341112. Epub 2015 Mar 4.


Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M.

J Virol. 2015 Jan 15;89(2):970-88. doi: 10.1128/JVI.02469-14. Epub 2014 Oct 29.


New vaccinia virus promoter as a potential candidate for future vaccines.

Di Pilato M, Mejías-Pérez E, Gómez CE, Perdiguero B, Sorzano CO, Esteban M.

J Gen Virol. 2013 Dec;94(Pt 12):2771-6. doi: 10.1099/vir.0.057299-0. Epub 2013 Sep 28.


Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Pérez-Jiménez E, Oliveros JC, Esteban M.

J Virol. 2013 Jun;87(12):6955-74. doi: 10.1128/JVI.03013-12. Epub 2013 Apr 17.


High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Sorzano CO, Esteban M.

PLoS One. 2012;7(6):e38859. doi: 10.1371/journal.pone.0038859. Epub 2012 Jun 8.

Supplemental Content

Loading ...
Support Center